• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Policy

AdvaMed president & CEO Scott Whitaker to participate in keynote interview at DeviceTalks Boston 2019

February 20, 2019 By Sarah Faulkner

DeviceTalks Boston 2019 - Scott Whitaker

WTWH Media and MassDevice.com announced today that Scott Whitaker, president and CEO of AdvaMed, will be a featured keynote speaker at DeviceTalks Boston 2019. DeviceTalks Boston, which takes place on June 5-6, 2019 at the Seaport World Trade Center, brings together engineering, product development and commercialization professionals to share the challenges and best practices of getting medical devices […]

Filed Under: Business/Financial News, Featured, Policy, Wall Street Beat Tagged With: AdvaMed, DeviceTalks Boston

House votes (again) to repeal medical device tax

July 25, 2018 By Sarah Faulkner

Medical device tax

The House voted 283 to 132 this week to repeal the 2.3% tax levied upon medical devices as part of the Affordable Care Act. The medical device tax, which has long been decried by the industry as a measure that squashes innovation and kills jobs, has been on hold since 2014. The tax’s moratorium was extended […]

Filed Under: Business/Financial News, Featured, Policy Tagged With: AdvaMed

Report: Trump to sign controversial law granting patients access to experimental drugs

May 29, 2018 By Sarah Faulkner

Pills

President Donald Trump is slated to approve legislation this week that will give terminally-ill patients access to experimental drugs that haven’t yet been cleared by the FDA. The “right-to-try” bill has sparked a great deal of controversy among policymakers and patient groups. While some, including the president, describe the effort as offering hope to patients […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Policy, Wall Street Beat Tagged With: FDA

Tribe taking steps to ‘ramp up’ drug patent business

May 22, 2018 By Sarah Faulkner

gavel

The Native American tribe wrapped up in litigation with generic pharmaceutical companies is trying to prove that its arrangement with Allergan (NYSE:AGN) reflects a legitimate move to boost its economy, according to court documents. The St. Regis Mohawk Tribe of New York found itself it the middle of a controversial deal this year after it agreed […]

Filed Under: Featured, Legal News, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Allergan, Mylan

Update: Novartis paid more than $1m to consulting company linked to Trump attorney Michael Cohen

May 9, 2018 By Sarah Faulkner

Novartis

Updated 5/9 to include new information about Novartis’ payments to Essential Consultants.  Novartis (NYSE:NVS) found itself in the middle of a national scandal today after it was revealed that the drugmaker paid more than $1 million to a consulting firm linked to President Donald Trump’s personal attorney, Michael Cohen. The shell company, Essential Consultants, was used by […]

Filed Under: Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Novartis

FDA chief suggests kickback law could be used to rein in drug prices

May 4, 2018 By Sarah Faulkner

Prescription drugs

Drug rebates paid between pharmaceutical companies and pharmacy benefit managers enjoy safe harbor status under federal kickback law, leaving them immune from legal scrutiny. But that could change, FDA chief Dr. Scott Gottlieb suggested yesterday at the FDA Law Institute’s annual meeting. The commissioner reportedly hinted that reinterpreting the law could help lower drug prices. […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Policy, Wall Street Beat Tagged With: FDA

FDA aims to curb ingredient list for drug compounders

March 26, 2018 By Sarah Faulkner

FDA

The FDA issued draft guidance last week designed to limit the list of pharmaceutical ingredients that drug compounding pharmacies can use to manufacture drugs in bulk that do not undergo the agency’s traditional approval process. The move comes in the wake of a deadly 2012 fungal meningitis outbreak that originated from contaminated drugs made in […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Policy, Regulatory/Compliance Tagged With: FDA

Report: Senators take aim at pharmacy “gag clauses”

March 16, 2018 By Sarah Faulkner

Pills

A bipartisan group of senators introduced two bills this week to stop “gag clauses” – conditions that prevent pharmacists from telling customers when they could save money on a prescription if they paid out of pocket rather than using insurance. These clauses are sometimes included in the contracts inked between the various parties that dictate […]

Filed Under: Featured, Pharmaceuticals, Policy

Controversial “right to try” bill fails in the House

March 14, 2018 By Sarah Faulkner

capitol hill

A controversial bill that would grant terminal patients access to experimental therapies failed yesterday in the House. Although the “right to try” effort didn’t muster up enough votes to send it to the Senate, majority leader Rep. Kevin McCarthy (R-CA) said in a statement that the fight wasn’t over. “We will try again, pass legislation, […]

Filed Under: Featured, Food & Drug Administration (FDA), Legal News, Pharmaceuticals, Policy

Report: Advocacy groups urge Congress to fund diabetes research programs

January 29, 2018 By Sarah Faulkner

diabetes

Advocacy groups have reportedly warned Congress that if lawmakers don’t find permanent funding solutions for diabetes research programs, it could jeopardize important work being done around the country to help people living with diabetes. Politicians on Capitol Hill have provided funding that will support the Special Diabetes Program and the Special Diabetes Program for Indians through […]

Filed Under: Diabetes, Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Juvenile Diabetes Research Foundation (JDRF), National Institutes of Health

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 8
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS